Celgene Price Target Cut to $102.00 (CELG)
JMP Securities decreased their price target on shares of Celgene (NASDAQ:CELG) from $205.00 to $102.00 in a research note issued on Friday. The firm currently has a “market outperform” rating on the stock. JMP Securities’ target price would suggest a potential upside of 17.76% from the stock’s previous close.
A number of other analysts have also recently weighed in on CELG. Analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note on Thursday. They now have a $182.00 price target on the stock. Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of Celgene in a research note on Thursday, June 19th. They now have a $112.50 price target on the stock, up previously from $105.00. Finally, analysts at Morgan Stanley initiated coverage on shares of Celgene in a research note on Monday, June 16th. They set an “equal weight” rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $99.19.
Shares of Celgene (NASDAQ:CELG) traded down 0.39% during mid-day trading on Friday, hitting $86.28. The stock had a trading volume of 1,026,996 shares. Celgene has a 52 week low of $116.71 and a 52 week high of $174.74. The stock’s 50-day moving average is $156.8 and its 200-day moving average is $156.1. The company has a market cap of $69.096 billion and a P/E ratio of 55.14.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.02. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.77 billion. During the same quarter in the previous year, the company posted $1.37 earnings per share. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. Analysts expect that Celgene will post $3.66 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.